Climb Bio (NASDAQ:CLYM) Stock Rating Upgraded by Leerink Partnrs

Climb Bio (NASDAQ:CLYM) was upgraded by equities research analysts at Leerink Partnrs to a “strong-buy” rating in a report released on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Climb Bio’s Q4 2024 earnings at ($0.15) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($1.74) EPS.

Separately, Leerink Partners started coverage on shares of Climb Bio in a research report on Monday. They issued an “outperform” rating and a $10.00 price objective on the stock.

Climb Bio Trading Down 3.4 %

CLYM opened at $3.15 on Monday. Climb Bio has a one year low of $2.35 and a one year high of $11.55.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.